This site is intended for
US Healthcare Professionals only.

Beau, 7 F508del/ F508del

Beau, 7

F508del/

F508del

People with CF pictured may or may not be taking SYMDEKO.

For patients with cystic fibrosis (CF) age 6 years and older who have responsive mutations1

Check Treatment Eligibility

Enter your patient's mutations below

SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is indicated for the treatment of patients with CF age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
Age: For patients 6 years and older

Eligible

Please check to see if the mutation was entered correctly.

Results